Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 905

Genomics Pioneer: Travels World To Discover Which Countries’ Healthcare Money Goes Furthest and Why

Genomics and BioPharma Pioneer!! — On this ideaXme (http://radioideaxme.com/) episode, I had the honor of being joined by Dr. William Haseltine — biologist, entrepreneur and philanthropist, known for his groundbreaking work on HIV/AIDS and the human genome, now focusing on the issues of healthcare costs, dementia care, and aging — #Ideaxme #Genomics #RegenerativeMedicine #BillHaseltine #Dementia #Biotechnology #Harvard #JamesWatson #WalterGilbert #DavidBaltimore #MIT #CraigVenter #Health #Wellness #Regeneration #Longevity #Aging #IraPastor #Bioquark #Regenerage

Ira Pastor, ideaXme exponential health ambassador, interviews Dr. William Haseltine, American biologist, entrepreneur and philanthropist, known for his groundbreaking work on HIV/AIDS and the human genome.

Ira Pastor Comments:

On today’s show we have a thought leader who sits amongst a rare group of people who have been responsible for creating many aspects of the modern biopharma / genomics / regenerative medicine system as we know it today.

Continue reading “Genomics Pioneer: Travels World To Discover Which Countries’ Healthcare Money Goes Furthest and Why” | >

Revel Pharma to repair collagen damaged by aging and diabetes using designer enzymes

For the past 10 years, Yale Professors David Spiegel and Jason Crawford have been working on tools to enable the development of glucosepane-cleaving drugs. Kizoo Technology Capital investors say now is the time to advance this groundbreaking research toward the clinic and are leading funding of a new company, Revel Pharmaceuticals Inc., founded by Drs. David Spiegel, Jason Crawford, and Aaron Cravens.

Kizoo leads the seed financing round at Revel, with Oculus co-founder Michael Antonov participating. SENS Research Foundation provided funding to the YaleGlycoSENS group for several years.

The long-lived collagen proteins that give structure to our arteries, skin, and other tissues are continuously exposed to blood sugar and other highly reactive molecules necessary for life. Occasionally, these sugar molecules will bind to collagen and form toxic crosslinks that alter the physical properties of tissues and cause inflammation. As a result, tissues slowly stiffen with aging, leading to rising systolic blood pressure, skin aging, kidney damage, and increased risk of stroke and other damage to the brain.

Stimulating Blood Vessel Growth Using FGF1 May Hold Promise for PD, Company Says

Stimulating the growth of blood vessels in the brain through the use of fibroblast growth factor 1 (FGF1) may hold promise as a strategy for treating Parkinson’s disease, according to a white paper released by Zhittya Genesis Medicine (ZGM). Clinical trials testing this theory are being planned.

The white paper is titled “Parkinson’s Disease: Therapeutic Angiogenesis as a Disease Modifying, Breakthrough Therapy?”

Google publishes largest ever high-resolution map of brain connectivity

Scientists from Google and the Janelia Research Campus in Virginia have published the largest high-resolution map of brain connectivity in any animal, sharing a 3D model that traces 20 million synapses connecting some 25,000 neurons in the brain of a fruit fly.

The model is a milestone in the field of connectomics, which uses detailed imaging techniques to map the physical pathways of the brain. This map, known as a “connectome,” covers roughly one-third of the fruit fly’s brain. To date, only a single organism, the roundworm C. elegans, has had its brain completely mapped in this way.

Connectomics has a mixed reputation in the science world. Advocates argue that it helps link physical parts of the brain to specific behaviors, which is a key goal in neuroscience. But critics note it has yet to produce any major breakthroughs, and they say that the painstaking work of mapping neurons is a drain on resources that might be better put to use elsewhere.

Brain organoids may shed light on seizures in Angelman syndrome

The mutation that causes Angelman syndrome makes neurons hyperexcitable, according to a study in brain organoids and mice1. The findings may help explain why about 90 percent of people with the syndrome experience seizures that do not respond to treatment.

Angelman syndrome is a rare genetic condition linked to autism. It is caused when the maternal copy of a gene called UBE3A is either missing or mutated. Apart from seizures, the condition is characterized by developmental delay, problems with balance and speech, and an unusually happy disposition.

The new study found that mutations in UBE3A suppress the production of proteins that keep the activity of ‘big potassium’ ion channels in check. These channels control the flow of large amounts of potassium ions passing through neurons. When the current increases in the absence of UBE3A, the neurons become exceptionally excitable.

/* */